Bertha Madras is a professor of psychobiology at McLean Hospital and Harvard Medical School, with a research focus on how drugs affect the brain. She is former deputy director for demand reduction in the White House Office of National Drug Control Policy. Data from 2015 indicate that 30 percent of current cannabis users harbor a use disorder \u2014 more Americans are dependent on cannabis than on any other illicit drug. Yet marijuana advocates have relentlessly pressured the federal government to shift marijuana from Schedule I \u2014 the most restrictive category of drug \u2014 to another schedule or to de-schedule it completely. Their rationale? \u201cStates have already approved medical marijuana\u201d; \u201crescheduling will open the floodgates for research\u201d; and \u201cmany people claim that marijuana alone alleviates their symptoms.\u201d<\/p>\n
Yet unlike drugs approved by the Food and Drug Administration, \u201cdispensary marijuana\u201d has no quality control, no standardized composition or dosage for specific medical conditions. It has no prescribing information or no high-quality studies of effectiveness or long-term safety. While the FDA is not averse to approving cannabinoids as medicines and has approved two cannabinoid medications, the decision to keep marijuana in Schedule I was reaffirmed in a 2015 federal court ruling. That ruling was correct. [https:\/\/www.washingtonpost.com\/news\/in-theory\/wp\/2016\/04\/29\/scientists-want-to-study-marijuana-big-pot-just-wants-to-sell-it\/]<\/p>\n
To reside in Schedules II-V and be approved for diagnosing, mitigating, treating or curing a specific medical condition, a substance or botanical must proceed through a rigorous FDA scientific process proving safety and efficacy. Not one form of \u201cdispensary marijuana\u201d with a wide range of THC levels \u2014 butane hash oil, smokables, vapors, edibles, liquids \u2014 has gone through this rigorous process for a single medical condition (let alone 20 to 40 conditions).<\/p>\n
To approve a medicine, the FDA requires five criteria to be fulfilled:<\/p>\n
1. The drug\u2019s chemistry must be known and reproducible.Evidence of a standardized product, consistency, ultra-high purity, fixed dose and a measured shelf life are required by the FDA. The chemistry of \u201cdispensary marijuana\u201d is not standardized. Smoked, vaporized or ingested marijuana may deliver inconsistent amounts of active chemicals. Levels of the main psychoactive constituent, THC, can vary from 1 to 80 percent. Cannabidiol (known as CBD) produces effects opposite to THC, yet THC-to-CBD ratios are unregulated.<\/p>\n
2. There must be adequate safety studies. \u201cDispensary marijuana\u201d cannot be studied or used safely under medical supervision if the substance is not standardized. And while clinical research on long-term side effects has not been reported, drawing from recreational users we know that marijuana impairs or degrades brain function, and intoxicating levels interfere with learning, memory, cognition and driving. Long-term use is associated with addiction to marijuana or other drugs, loss of motivation, reduced IQ, psychosis, anxiety, excessive vomiting, sleep problems and reduced lifespan. Without a standardized product and long-term studies, the safety of indefinite use of marijuana remains unknown.<\/p>\n
3. There must be adequate and well-controlled studies proving efficacy. Twelve meta-analyses of clinical trials scrutinizing smoked marijuana and cannabinoids conclude that there is no or insufficient evidence for the use of smoked marijuana for specific medical conditions. There are no studies of raw marijuana that include high-quality, unbiased, blinded, randomized, placebo-controlled or long-duration trials.<\/p>\n
4. The drug must be accepted by well-qualified experts. Medical associations generally call for more cannabinoid research but do not endorse smoked marijuana as a medicine. The American Medical Association: \u201cCannabis is a dangerous drug and as such is a public health concern\u201d; the American Academy of Child and Adolescent Psychiatry: \u201cMedicalization\u201d of smoked marijuana has distorted the perception of the known risks and purposed benefits of this drug;\u201d the American Psychiatric Association: \u201cNo current scientific evidence that marijuana is in any way beneficial for treatment of any psychiatric disorder \u2026 the approval process should go through the FDA.\u201d<\/p>\n
5. Scientific evidence must be widely available. The evidence for approval of medical conditions in state ballot and legislative initiatives did not conform to rigorous, objective clinical trials nor was it widely available for scrutiny.<\/p>\n
Marijuana fails to meet any of these five criteria for accepted medical use in the United States. At present, it belongs in Schedule I.<\/p>\n
Is Schedule I drug a roadblock to marijuana research? Not really. The major roadblock to five proposed studies at the California Center for Medicinal Cannabis Research was not the Schedule I label, but the scarcity of patients willing to enrol in five major clinical trials. The process for marijuana research could be streamlined by Drug Enforcement Administration oversight and expansion of marijuana production, and a special sub-category of Schedule I could further reduce paperwork. But moving marijuana to Schedule II \u201cto promote research\u201d is conceivably unethical, as marijuana would then be designated a safe and effective medicine in the absence of high-quality evidence.<\/p>\n
Should we dismiss heartfelt appeals from people suffering various diseases, knowing that a host of chronic, debilitating ailments are inadequately managed? Human stories should not be ignored, and rigorous, creative solutions can be formulated in response. However, the \u201cmarijuana mess\u201d and its \u201cnew realities\u201d were created not by the federal government but by political processes designed to circumvent the FDA, the only federal agency that safeguards our nation\u2019s medicines. If the more than $100 million spent on ballot and legislative initiatives instead had been used for quality clinical trials, our nation would know much more about the therapeutic potential of cannabinoids. Instead, \u201cdispensary marijuana\u201d is evolving into a human experiment without informed consent.<\/p>\n
We revere the brain more than other body part because it is the repository of our humanity. When a brain disease strikes, it can fundamentally transform an individual. We schedule and restrict psychoactive drugs because they can negatively affect the human brain and behavior. Of brain diseases, substance use disorders are among the most lamentable forms of human anguish. They are also among the most preventable.<\/p>\n
Source:\u00a0 www.washingtonpost.com\/news\/in-theory\/wp\/2016\/04\/29\/5<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Bertha Madras is a professor of psychobiology at McLean Hospital and Harvard Medical School, with a research focus on how drugs affect the brain. She is former deputy director for demand reduction in the White House Office of National Drug Control Policy. Data from 2015 indicate that 30 percent of current cannabis users harbor a […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30,90,60],"tags":[],"class_list":["post-11559","post","type-post","status-publish","format-standard","hentry","category-cannabis-marijuana","category-global-drug-legalisation-efforts","category-marijuana-and-medicine"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/11559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=11559"}],"version-history":[{"count":0,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/11559\/revisions"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=11559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=11559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=11559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}